CSPC Pharmaceutical (CSPC) is a vertically integrated pharmaceutical company in China with a diversified portfolio focusing on cardiovascular diseases and oncology, strong sales team of ~10k sales people in China and a solid research & development (R&D) pipeline to support a future stream of new drug additions. The firm has invested significantly in research & development (~15% of finished drug revenue or CNY3b was spent on R&D in 2021) to increase its focus on innovative drugs. Major product brands include NBP, Duomeisu, Jinyouli and Keaili. For bulk drugs, key products include Vitamin C, caffeine and antibiotics. Over the medium term, we expect organic earnings growth to be supported by the company’s focus on R&D and positive shifts in sales mix. Following deals done in 2018 involving mostly early stage drug candidates, management is open to licensing deals to enhance its portfolio and aims to license new late-stage drugs near to commercial stage. Balance sheet is in net cash position. Potential share price volatility may result from concerns over pricing pressure due to ongoing sector reforms. Further, given the currentweakness in the Chinese economy and the potential of further lockdowns, there may be further downsides to the stock price. While the fundamentals are decent, I am holding off purchases of this stock for now till I see price stability. At the moment, it is too volatilefor me.
DYODD
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- hh488·2022-11-28Just bought the minimum last week.10Report
- Zack44·2022-11-27Keeping our fingers crossed 🤞🤞🤞10Report
- Light Randy·2022-11-30thank for the info8Report
- Lord Tan·2022-11-30Make the blue pill5Report
- Andie8392·2022-11-30thanks for sharing5Report
- Kaka85·2022-12-03GreatLikeReport
- AnnieNah·2022-12-03Thanks1Report
- 哈儿jr·2022-12-03👌2Report
- Xpand·2022-12-03Ok1Report
- 小方66·2022-12-03👍1Report
- newtoUS·2022-12-03okLikeReport
- newtoUS·2022-12-03oLikeReport
- 嘞撸虎7·2022-12-03阅LikeReport
- Domiqta·2022-12-03OkLikeReport
- GoldApe·2022-12-02[smile]LikeReport
- teckwei·2022-12-02HihihiLikeReport
- YingDa·2022-12-02OkLikeReport
- Aindra·2022-12-02🤙LikeReport
- Todkie·2022-12-02Nice1Report
- redmerlion·2022-12-02Ok1Report